Atlas Trials

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Clinical trial NCT05276492 · TERMINATED

Trial details

NCT number
NCT05276492
Sponsor
University of Chicago
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Prostate CancerProstate AdenocarcinomaProstate NeoplasmProstate Cancer Metastatic
Start date
2023-01-24
Primary completion
2024-11-16
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.